NCT02157558View on ClinicalTrials.gov

An Open-Label Drug-Drug Interaction Study of Telotristat Etiprate and Fexofenadine in Healthy Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

July 31, 2014

Primary Completion Date

August 31, 2014

Conditions
Drug Interactions
Interventions
DRUG

Fexofenadine

All subjects will receive 180 mg fexofenadine

DRUG

Telotristat etiprate

All subjects will receive 500 mg (2 X 250 mg tablets) telotristat etiprate tablets three times daily

Trial Locations (1)

75247

Lexicon Investigational Site, Dallas

Sponsors
All Listed Sponsors
lead

Lexicon Pharmaceuticals

INDUSTRY